Human uPAR Antibody Summary
Leu23-Arg303
Accession # Q03405
Applications
Human uPAR Sandwich Immunoassay
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of uPAR in Human Blood Granulocytes by Flow Cytometry. Human peripheral blood granulocytes were stained with Mouse Anti-Human uPAR Monoclonal Antibody (Catalog # MAB807, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B). View our protocol for Staining Membrane-associated Proteins.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: uPAR
The urokinase-type Plasminogen Activator (uPA) is one of two activators that converts the extracellular zymogen plasminogen to plasmin, a serine protease that is involved in a variety of normal and pathological processes that require cell migration and/or tissue destruction. uPA is synthesized and released from cells as a
single-chain (sc) pro-enzyme with limited enzymatic activity and is converted to an active two-chain (tc) disulfide-linked active enzyme by plasmin and other specific proteinases. Both the scuPA and tcuPA bind with high-affinity to the cell surface via the glycosyl phosphatidylinositol-linked receptor uPAR which serves to localize the uPA proteolytic activity. The enzymatic activity of scuPA has also been shown to be enhanced by binding to uPAR. Independent of their proteolytic activity, the uPA/uPAR interaction also initiates signal transduction responses resulting in activation of protein tyrosine kinases, gene expression, cell adhesion, and chemotaxis. uPAR can interact with integrins to suppress normal integrin adhesive function and promote adhesion to vitronectin through a high affinity vitronectin binding site on uPAR. uPAR cDNA encodes a 335 amino acid (aa) residue precursor protein with a 22 aa residue signal peptide, five potential N-linked glycosylation sites and a
C‑terminal GPI-anchor site. An alternate spliced variant of uPAR encoding a secreted soluble form of uPAR also exists. Human and mouse uPAR share approximately 60% aa sequence identity and the receptor-ligand interaction is strictly species-specific.
Product Datasheets
Citations for Human uPAR Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
20
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Simultaneous stabilization of actin cytoskeleton in multiple nephron-specific cells protects the kidney from diverse injury
Authors: K Mukherjee, C Gu, A Collins, M Mettlen, B Samelko, MM Altintas, YR Sudhini, X Wang, R Bouley, D Brown, BP Pedro, SL Bane, V Gupta, PT Brinkkoett, H Hagmann, J Reiser, S Sever
Nature Communications, 2022-05-03;13(1):2422.
-
New Blocking Antibodies against Novel AGR2–C4.4A Pathway Reduce Growth and Metastasis of Pancreatic Tumors and Increase Survival in Mice
Authors: Thiruvengadam Arumugam, Defeng Deng, Laura Bover, Huamin Wang, Craig D. Logsdon, Vijaya Ramachandran
Molecular Cancer Therapeutics
-
Proteomics profiling identifies extracellular vesicles' cargo associated with tumour cell induced platelet aggregation
Authors: N McNamee, LR de la Fuen, MJ Santos-Mar, L O'Driscoll
BMC Cancer, 2022-09-29;22(1):1023.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
E4 engages uPAR and enolase-1 and activates urokinase to exert antifibrotic effects
Authors: S Sharma, T Watanabe, T Nishimoto, T Takihara, L Mlakar, XX Nguyen, M Sanderson, Y Su, RA Chambers, C Feghali-Bo
JCI Insight, 2021-12-22;6(24):.
Species: Human
Sample Types: Cell Fractions
Applications: Immunoprecipitation, Western Blot -
Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells
Authors: M van Veen, E Matas-Rico, K van de Wet, D Leyton-Pui, KM Kedziora, V De Lorenzi, Y Stijf-Bult, B van den Br, K Jalink, N Sidenius, A Perrakis, WH Moolenaar
Elife, 2017-08-29;6(0):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
The periodontal pathogen Porphyromonas gingivalis preferentially interacts with oral epithelial cells in S phase of the cell cycle
Authors: FB Al-Taweel, CW Douglas, SA Whawell
Infect Immun, 2016-06-23;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.
Authors: Gilder A, Jones K, Hu J, Wang L, Chen C, Carter B, Gonias S
J Biol Chem, 2015-04-02;290(24):14798-809.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
Intracellular modifiers of integrin alpha 6p production in aggressive prostate and breast cancer cell lines.
Authors: Kacsinta A, Rubenstein C, Sroka I, Pawar S, Gard J, Nagle R, Cress A
Biochem Biophys Res Commun, 2014-10-22;454(2):335-40.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
Authors: Huang J, Liu G, Zhang Y, Cui Z, Wang F, Liu X, Chu R, Zhao M
BMC Med, 2014-05-20;12(0):81.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
Authors: Tersteeg C, de Maat S, De Meyer S, Smeets M, Barendrecht A, Roest M, Pasterkamp G, Fijnheer R, Vanhoorelbeke K, de Groot P, Maas C
Circulation, 2014-01-21;129(12):1320-31.
Species: Human
Sample Types: Whole Cells
Applications: Functional Assay -
Activation of the plasma kallikrein-kinin system on human lung epithelial cells.
Authors: Vergiliana JF, Asokananthan N, Stewart GA
Biol. Chem., 2010-09-01;391(9):1067-77.
Species: Human
Sample Types: Whole Cells, Whole Tissue
Applications: Flow Cytometry, ICC, IHC-P -
Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine.
Authors: Hu H, Kwun J, Aizenstein BD, Knechtle SJ
Transplantation, 2009-06-27;87(12):1814-20.
Species: Human
Sample Types: Urine
Applications: Antibody Array Development -
AP-1-controlled hepatocyte growth factor activation promotes keratinocyte migration via CEACAM1 and urokinase plasminogen activator/urokinase plasminogen receptor.
Authors: Schnickmann S, Camacho-Trullio D, Bissinger M, Eils R, Angel P, Schirmacher P, Szabowski A, Breuhahn K
J. Invest. Dermatol., 2008-11-20;129(5):1140-8.
Species: Human
Sample Types: Cell Lysates, Whole Cells
Applications: Neutralization, Western Blot -
Development and validation of sandwich ELISA microarrays with minimal assay interference.
Authors: Gonzalez RM, Seurynck-Servoss SL, Crowley SA
J. Proteome Res., 2008-04-19;7(6):2406-14.
Species: Human
Sample Types: Serum
Applications: ELISA Microarray Development -
Urokinase-type plasminogen activator modulates airway eosinophil adhesion in asthma.
Authors: Brooks AM, Bates ME, Vrtis RF, Jarjour NN, Bertics PJ, Sedgwick JB
Am. J. Respir. Cell Mol. Biol., 2006-05-25;35(4):503-11.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
LDL-receptor-related protein regulates beta2-integrin-mediated leukocyte adhesion.
Authors: Spijkers PP, da Costa Martins P, Westein E, Gahmberg CG, Zwaginga JJ, Lenting PJ
Blood, 2004-08-24;105(1):170-7.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Differences in integrin expression and signaling within human breast cancer cells
Authors: Aliakbar Taherian, Xinlei Li, Yongqing Liu, Thomas A Haas
BMC Cancer
-
Variability in CKD Biomarker Studies: Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Kidney Disease Progression in the Chronic Kidney Disease in Children (CKiD) Study
Authors: Alison G. Abraham, Yunwen Xu, Jennifer L. Roem, Jason H. Greenberg, Darcy K. Weidemann, Venkata S. Sabbisetti et al.
Kidney Medicine
-
Knockdown of Notch1 inhibits nasopharyngeal carcinoma cell growth and metastasis via downregulation of CCL2, CXCL16, and uPA
Authors: Huajiao Guo, Fuhao Wang, Yuwen Diao, Zhe Zhang, Qiuyan Chen, Chao‐Nan Qian et al.
Molecular Carcinogenesis
-
Macrophage-Dependent Cleavage of the Laminin Receptor alpha 6 beta 1 in Prostate Cancer
Authors: Isis C. Sroka, Cynthia P. Sandoval, Harsharon Chopra, Jaime M. C. Gard, Sangita C. Pawar, Anne E. Cress
Molecular Cancer Research
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human uPAR Antibody
Average Rating: 5 (Based on 3 Reviews)
Have you used Human uPAR Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
The impact of prolactin treatments was used to assess human uPAR expression using western blot. Results were reliable, the intra-assay variation was low, and the obtained outcomes were in agreement with reported results from the literature. In the picture, the densitometric analysis from western blot is depicted, showing a control (without prolactin treatment), a pharmacological treatment using PRL treatments, a specific 16 kDa PRL treatment, and methotrexate as PRLR inhibitor.
